lifestyle.gooddecisions.com

Author: Insilico Medicine

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

February 11, 2026
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

February 3, 2026
Up to 31.3% Body Weight Loss, Insilico Medicine Nominates AI-Powered GIPR Antagonist ISM0676 as Preclinical Candidate, Showing Synergistic Efficacy in Combination Therapy

January 29, 2026
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor

January 23, 2026
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines

January 23, 2026
Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

January 20, 2026
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease

January 12, 2026
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

January 4, 2026
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025’s Largest Hong Kong Biotech IPO

December 30, 2025
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

December 13, 2025